Navigation Links
Clinical Trial Concluded For New Wrinkle Treatment
Date:7/24/2008

CosmetaLife clinical trial results could lead to availability of more natural, longer lasting, cost-effective treatment for deep lines and wrinkles by 2009.

St. Paul, Minn. (PRWEB) July 24, 2008 -- Gel-Del Technologies, a St. Paul, Minnesota based biomedical device company announced that it has concluded clinical trials of CosmetaLife, a dermal filler injection that company officials say holds potential to be a more effective alternative to currently available treatments for deep lines and wrinkles that activates a more natural skin correction.

The company began clinical trials of CosmetaLife, a gel-particle product for injection to correct wrinkles, at six U.S. sites in 2006. The company hopes to introduce the product to the rapidly growing $1 billion cosmetic augmentation market in 2009.

David B. Masters, Ph.D., Gel-Del Technologies founder and president, is the inventor of the technology and its related products. Masters said, "It is exciting to see the first human use of this technology over the past 19 months. Based on the results of our 12 month clinical study, CosmetaLife provides a better early performance than hyaluronic acid products, and a lasting effect expected to persist longer due to an actual dermal correction."

Masters continued, "We are pleased with the results of the CosmetaLife trials. As expected, they show our product compares more favorably to Restylane for the first three months and equally to Restylane at the 12-month mark. We are eager to complete the next steps with the FDA."

The proprietary technology used to produce CosmetaLife is covered by 9 U.S. and 26 foreign patents and patent applications
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ican women using Carraguard had no decrease in inf...4 (HealthDay News) -- A microbicidal vaginal gel c...fection. , That,s the conclusion of a study tha...gative women at three sites in South Africa. , ...o gel and told to use one applicator of gel and a ...
(Date:12/4/2008)..., Dec. 4 Aurora Health Care is ram... D supplements. Aurora,s Care Management,Clinical...ucate all Aurora,caregivers about the benefits of...g evidence that higher Vitamin D levels may improv...porosis, certain muscle conditions and,seasonal d...
(Date:12/4/2008)...N, Dec. 4 The U.S. Gove...Development (USAID), is providing an additional $6...abwe. This assistance is in addition to the $4 mi...gram USAID is already implementing in Zimbabwe. ,... working alongside the international community to ...
(Date:12/4/2008)...cts similar to those seen with standard dose of da...c. 4 (HealthDay News) -- A high dose of the chemot...tients with previously untreated acute myeloid leu...red by the U.S. National Cancer Institute (NCI) sh...row. This study included 633 patients, aged 16 to ...
Breaking Medicine News(10 mins):Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2
...ming at getting the children in northern communiti...h Promotion Minister, Jim Watson, the government w... carrot sticks, apples and other fresh fruit and v... children in elementary schools in Northern Ontari...
... found to have a role in the treatment of lung dis...cent research. // The results of the study have b...and Journal of Medicine, which has revealed that t...tment of cancer could slightly improve lung functi...
...o a vasectomy reversal could be at an increased ri...ead to birth defects in children. // The research...ersity, Bangkok, Thailand. The study was conducted...rocedure which does not interfere with sperm produ...
...daily doses of insulin injections. However in peop...f the pancreatic tissue// could help solve the pro...lindness, amputation, kidney failure, and heart di...early enough organ donors available for transplant...
Other Medicine News:Health News:Obesity Tackled at School Level 2Health News:Cancer Drug to Treat Scleroderma Lung Disease 2Health News:Vasectomy Reversal to Lead to Birth Defects 2Health News:Transplanted Pancreatic Tissue Could Help Diabetics 2
(Date:12/2/2008)...ratories, a leading clinical-diagnostics and biom...ogy and allergy assays, announced that it has laun...nts whose immune systems may be compromised due to... drugs, or because they are taking immuno-suppress...e company launched the two new assays, the T Cell...
(Date:12/2/2008)...Therapeutics, Inc., a,privately held biopharmaceu...hase 3 trials evaluating its lead investigational ...ints. HZT-501, a novel, proprietary fixed-dose,co...ine, demonstrated a,statistically significant red...lammatory drug (NSAID)-induced upper gastrointesti...
(Date:12/1/2008)...w research has found that the availability of a po...r in an emergency room can significantly increase ...ally life-saving treatment. Results of the study, ...em Hospital in Salem, Mass., will be presented tod...ty of North America (RSNA). , , "The hospit...
(Date:12/1/2008)... -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) r...ld,s leading medical journals, results of clinical...ntal compound tasimelteon (VEC-162). The publicat...agonist tasimelteon (VEC-162) for transient insomn...ed multicentre trials." Results are reported from ...
Breaking Medicine Technology:IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Caregivers Protest Statewide to Stop Daughters of Charity From Silencing the Voice of Caregivers 26 Threatening Patient Care 23128 1Caregivers Protest Statewide to Stop Daughters of Charity From Silencing the Voice of Caregivers 26 Threatening Patient Care 23128 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and 248 3 Million Financing 6353 1Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and 248 3 Million Financing 6353 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and 248 3 Million Financing 6353 3Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and 248 3 Million Financing 6353 4SXC Health Solutions announces informedRx renewal contract with The University of Michigan 23122 1SXC Health Solutions announces informedRx renewal contract with The University of Michigan 23122 2Breastfeeding com Launches First Ever Social Network for Birth Related Medical Professionals 23118 1Breastfeeding com Launches First Ever Social Network for Birth Related Medical Professionals 23118 2
...IDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ ...m the first of two,Phase 3 clinical studies to ass...n investigational, non-antibiotic, polymer,therapy...d diarrhea,(CDAD). The second Phase 3 study of tol...pected later this year. , In this first Phase 3 st...
..., Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOP...positive interim data,from an ongoing phase II tri...treat advanced sarcoma patients was presented at t...ting held July 5-8,2007 in Lugano, Switzerland. T...O-201) In Advanced Sarcoma," was presented by,Rash...
Other Medicine Technology:Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
Non-sterile Silicone Tubing
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla
Diamond knife tray with silicone inserts to securely hold the diamond knife.
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments.
Medicine Products: